http://www.reportbuyer.com/rss.htmlIn this section you will find information products, including market research reports, on the following sector: Drug Deliveryen-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/gene_therapy.htmlGene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Genes and DNA are now being introduced without the use of vectors and various techniques are being used to modify the function of genes in vivo without gene transfer. If one adds to this the cell therapy particularly with use of genetically modified cells, the scope of gene therapy becomes much broader. e4eac581d0983ed43f3082909590041bSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/personalized_medicine.htmlThe aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. d0a6f9815eaf13e9e1ec0e1c1123aca1Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/drug_delivery_partnering_agreements_pharma_biotech.htmlThe Drug Delivery Partnering Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology or drug delivery-enabled product candidates. 331792447d043cc948d0e1f8dff77926Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/molecular_diagnostics.htmlThis report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, biochips, nanotechnology and proteomic technologies. Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. 8686177a995968c9ff13eda476230c33Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/cardiovascular_drug_delivery.htmlDrug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. d11b0cf0da014b35a6273e38edd1bf7fSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/drug_delivery_central_nervous_system_diseases.htmlThe delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e. g. a339fbb2aaefde77e6c4e9dc3b5c8952Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/drug_delivery_markets_implantable_injectable_needle_free_delivery_systems.htmlWith pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama's Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. 185b4be6439fa7530c062202d8640c1dWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/insulin_delivery_systems_market_analysis_2008_2012.htmlThe increasing number of diabetes patients globally is proving a boon for diabetes drugs market. The number of diabetic patients in the world is estimated to reach at more than 250 Million in 2008. The governments worldwide are taking initiatives on various research and development projects in order to improve drug delivery techniques. 60a1ec4ade6bd9d581423427abb68ee0Sat, 08 Aug 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/drug_delivery_markets.htmlSince our last edition of this report in 2007, The oral drug delivery market is the largest segment of the drug delivery market, and there's no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it's no surprise that the oral delivery drug market is a $35 billion industry and expected to grow as much as ten percent per year. Kalorama's Drug Delivery Markets: Oral Delivery provides the definitive break down of the market for oral delivery drug markets. 39a8389724230bea9c45f094ac360c21Tue, 07 Jul 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/top_40_transdermal_drug_delivery_technology_companies_worldwide.htmlThe US Food and Drug Administration (FDA) approved the first transdermal patch products in 1981. These delivery systems provided the controlled systemic absorption of scopolamine for the prevention of motion sickness (Transderm-Scop) and nitroglycerine for the prevention of angina pectoris associated with coronary artery disease (Transderm-Nitro). Until the commercial success of these products, it was still perceived too difficult for an active molecule to overcome the barrier properties of human skin and penetrate into the blood system at adequate quantities to elicit a therapeutic effect. 74d0cec8d972617df73fa1cb627aab5aTue, 07 Jul 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/nucleic_acid_drug_delivery_technologies_players_products_prospects_2018_volume_iii.htmlNucleic Acid Delivery The nucleic acid delivery market is maturing with over 1,450 clinical trials underway worldwide. The majority of these are in early clinical development (approximately 60%) with just over 3% in Phase III trials. Our analysis indicates that up to 35 novel nucleic acid products could reach the market within our forecasting period (2008-2018). c435df9551f429a725c92fbf8dc35f1eSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/drug_delivery_technologies_players_products_prospects_2018.htmlDrug Delivery Technology: Assessing its potential The time when advanced drug delivery was merely a means for profitable product life extension has gone. Drug delivery is now a major component of the pharmaceutical industry's future and critical to bringing novel therapies to market. Indeed, without the ability to effectively deliver targeted drugs in therapeutically significant quantities, many of the gene-based agents in research would not be viable. 236eb62e002620a9b2ee2102023e4d2dSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/indian_healthcare_sector_industry_profile.htmlThis industry profile helps to gain an insight into the evolution of the industry and competitive dynamics prevalent in the market. It discusses the significant developments in the industry and analyzes the key trends and issues. The profile provides inputs in strategic business planning of industry professionals. 060a2de925b228d76b1ecd831fd16df9Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/controlled_release_players_products_prospects_2018_volume_i.htmlControlled-release Delivery The controlled-release market was worth nearly US$21 billion globally in 2008. The sector is dominated by the launch of oral controlled-release formulations in key therapeutic areas such as the central nervous system, cardiovascular, metabolic and respiratory diseases. The growth of controlled-release delivery continues to be fuelled by line extensions helping to offset the impact of generic erosion. 66e7cef366ade7378916991629d889bbSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/targeted_drug_delivery_technologies_players_products_prospects_2018_volume_iv.htmlTargeted Delivery By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8. 5 billion. Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. e1eab1ef6403f53594804fd62c15d284Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/uk_healthcare_sector_industry_profile.htmlThis industry profile helps to gain an insight into the evolution of the industry and competitive dynamics prevalent in the market. It discusses the significant developments in the industry and analyzes the key trends and issues. The profile provides inputs in strategic business planning of industry professionals. 409daa451e63dda6d9d54fe6d495c2c7Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/canadian_healthcare_sector_industry_profile.htmlThis industry profile helps to gain an insight into the evolution of the industry and competitive dynamics prevalent in the market. It discusses the significant developments in the industry and analyzes the key trends and issues. The profile provides inputs in strategic business planning of industry professionals. 2cc74aa12fbae243fee8aff712d243adSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/us_healthcare_sector_industry_profile.htmlThis industry profile helps to gain an insight into the evolution of the industry and competitive dynamics prevalent in the market. It discusses the significant developments in the industry and analyzes the key trends and issues. The profile provides inputs in strategic business planning of industry professionals. 8e05327b438b81e97146d6505e690a88Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/u_s_injectable_drug_pipeline.htmlThis Frost & Sullivan research service titled U. S. Injectable Drug Pipeline provides an assessment of injectable drugs in clinical development in the United States, including pipeline lists by phase, commentary on selected products, and an analysis of the leading areas of pipeline compound distribution. b1c75c521477de15ad2d81310f700909Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Drug Deliveryhttp://www.reportbuyer.com/pharma_healthcare/drug_delivery/u_s_market_drug_eluting_bare_metal_stents_2009.htmlIn 2008, the U. S. market for drug eluting stents was valued at $1. 95 billion, representing an increase of 1. 7337a0ef8c7a0718a16da93bd400d5cfTue, 05 May 2009 12:00:00 GBPharma & Healthcare/Drug Delivery